Daewon Pharmaceutical Co. Ltd. (KO:003220) — Market Cap & Net Worth
Market Cap & Net Worth: Daewon Pharmaceutical Co. Ltd. (003220)
Daewon Pharmaceutical Co. Ltd. (KO:003220) has a market capitalization of $118.96 Million (₩175.54 Billion) as of October 11, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18564 globally and #877 in its home market, demonstrating a 5.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Daewon Pharmaceutical Co. Ltd.'s stock price ₩8190.00 by its total outstanding shares 21433439 (21.43 Million).
Daewon Pharmaceutical Co. Ltd. Market Cap History: 2015 to 2026
Daewon Pharmaceutical Co. Ltd.'s market capitalization history from 2015 to 2026. Data shows change from $178.44 Million to $118.96 Million (-5.12% CAGR). Check Daewon Pharmaceutical Co. Ltd. stock price for real-time trading data and today's change.
Daewon Pharmaceutical Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Daewon Pharmaceutical Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of Daewon Pharmaceutical Co. Ltd. for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.00x
Daewon Pharmaceutical Co. Ltd.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $206.82 Million | $240.72 Billion | $20.24 Billion | 0.00x | 0.01x |
| 2017 | $234.40 Million | $265.46 Billion | $10.74 Billion | 0.00x | 0.02x |
| 2018 | $189.78 Million | $286.65 Billion | $23.74 Billion | 0.00x | 0.01x |
| 2019 | $212.66 Million | $317.83 Billion | $27.29 Billion | 0.00x | 0.01x |
| 2020 | $247.68 Million | $308.50 Billion | $17.64 Billion | 0.00x | 0.01x |
| 2021 | $225.94 Million | $354.18 Billion | $6.99 Billion | 0.00x | 0.03x |
| 2022 | $267.10 Million | $478.88 Billion | $31.94 Billion | 0.00x | 0.01x |
| 2023 | $227.46 Million | $526.95 Billion | $23.92 Billion | 0.00x | 0.01x |
| 2024 | $206.98 Million | $598.16 Billion | $14.21 Billion | 0.00x | 0.01x |
| 2025 | $173.58 Million | $605.43 Billion | -$1.38 Billion | 0.00x | N/A |
Competitor Companies of 003220 by Market Capitalization
Companies near Daewon Pharmaceutical Co. Ltd. in the global market cap rankings as of October 11, 2026. See net asset quality index of Daewon Pharmaceutical Co. Ltd. to understand what proportion of total assets are financed by equity.
Key companies related to Daewon Pharmaceutical Co. Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
Daewon Pharmaceutical Co. Ltd. Historical Marketcap From 2015 to 2026
Between 2015 and today, Daewon Pharmaceutical Co. Ltd.'s market cap moved from $178.44 Million to $ 118.96 Million, with a yearly change of -5.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩118.96 Million | -31.46% |
| 2025 | ₩173.58 Million | -16.14% |
| 2024 | ₩206.98 Million | -9.00% |
| 2023 | ₩227.46 Million | -14.84% |
| 2022 | ₩267.10 Million | +18.22% |
| 2021 | ₩225.94 Million | -8.78% |
| 2020 | ₩247.68 Million | +16.47% |
| 2019 | ₩212.66 Million | +12.06% |
| 2018 | ₩189.78 Million | -19.04% |
| 2017 | ₩234.40 Million | +13.33% |
| 2016 | ₩206.82 Million | +15.91% |
| 2015 | ₩178.44 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Daewon Pharmaceutical Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $118.96 Million USD |
| MoneyControl | $118.96 Million USD |
| MarketWatch | $118.96 Million USD |
| marketcap.company | $118.96 Million USD |
| Reuters | $118.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Daewon Pharmaceutical Co. Ltd.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more